Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Chromatogr Sci ; 58(6): 562-568, 2020 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-32303742

RESUMO

A simple and accurate chiral liquid chromatographic method was developed for enantiomeric resolution and determination of 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide (EAI045). The enantiomers of EAI045 were baseline resolved on a Chiralpak AD-H (250 mm × 4.6 mm, 5 µm) column using a mobile phase system containing n-hexane: 2-propanol (75: 25 v/v) at a flow rate of 1 mL min-1 at 30°C. The eluted analytes were subsequently detected with an ultraviolet detector at 254 nm. The effects of organic modifiers and temperature on the enantioselectivity and resolution of the enantiomers were evaluated. The calibration curves were plotted within the concentration range between 2 and 600 µg mL-1 (n = 11), and recoveries between 98.74% and 101.52% were obtained, with relative standard deviation < 1.4%. The limit of detection and limit of quantitation for R-enantiomer were 0.94 and 3.07 µg mL-1 and for S-enantiomer were 0.86 and 2.84 µg mL-1, respectively. The validated method was found to be suitable for enantiomeric separation and sufficiently accurate for the determination of enantiomeric purity of EAI045 in bulk drugs.


Assuntos
Benzenoacetamidas , Cromatografia Líquida/métodos , Tiazóis , Amilose/análogos & derivados , Amilose/química , Animais , Benzenoacetamidas/sangue , Benzenoacetamidas/química , Benzenoacetamidas/isolamento & purificação , Benzenoacetamidas/farmacocinética , Limite de Detecção , Modelos Lineares , Camundongos , Fenilcarbamatos/química , Reprodutibilidade dos Testes , Estereoisomerismo , Tiazóis/sangue , Tiazóis/química , Tiazóis/isolamento & purificação , Tiazóis/farmacocinética
2.
Molecules ; 23(9)2018 Sep 07.
Artigo em Inglês | MEDLINE | ID: mdl-30205508

RESUMO

The aim of this study was to investigate the estrogen-like effects of 2-phenylacetamide (PA), which is the main compound isolated from the seeds of Lepidium apetalum Willd (LA). Results showed that LA and PA could promote the proliferation of MCF-7 cells. The mouse uterine weight test showed that, LA and PA could increase the uterus index of immature female mice, and the levels of luteinizing hormone (LH) and estrogen (E2). LA could increase the expression of ERα and ERß, while PA could increase the expression of ERα, ERß and GPR30 in the uterus and MCF-7 cells. In addition, co-incubation of the estrogen receptor blocker with LA or PA abolished the inductive effect of the proliferation. PA has estrogenic activities and was the material basis of LA that played the estrogenic effect. LA and PA might be used for the treatment of perimenopause syndrome in a novel application.


Assuntos
Benzenoacetamidas/isolamento & purificação , Benzenoacetamidas/farmacologia , Estrogênios/farmacologia , Lepidium/embriologia , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/farmacologia , Sementes/química , Animais , Proliferação de Células/efeitos dos fármacos , Feminino , Humanos , Hormônio Luteinizante/metabolismo , Células MCF-7 , Camundongos , Receptores de Estrogênio/antagonistas & inibidores , Receptores de Estrogênio/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Útero/efeitos dos fármacos , Útero/metabolismo
3.
Comput Biol Med ; 42(5): 542-7, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22381026

RESUMO

The incidence of fungal disease has increased dramatically over the past decades, mainly due to the emergence and transmission of antifungal resistance within the fungal pathogens. The present study investigates the use of novel antifungal compound 4-Phenyl-1-Napthyl Phenyl Acetamide (4P1NPA), isolated from marine Streptomyces sp. DPTB16 as a potent antifungal drug. The preclinical studies and molecular docking for 4P1NPA against Cytochrome P450 51 (CYP 51) were performed using in silico pharmacology and docking tools. The finding reveals the drug likeliness of 4P1NPA and satisfactory interaction of 4P1NPA with CYP 51. These results collectively evidence the use of 4P1NPA as a drug to treat fungal infections. On the whole, we highlight the findings of this research will be helpful to design 4P1NPA as novel antifungal drug to defend the emerging antifungal resistance.


Assuntos
Antifúngicos/farmacologia , Benzenoacetamidas/farmacologia , Streptomyces/química , Animais , Antifúngicos/farmacocinética , Antifúngicos/toxicidade , Benzenoacetamidas/isolamento & purificação , Benzenoacetamidas/farmacocinética , Inibidores das Enzimas do Citocromo P-450 , Avaliação Pré-Clínica de Medicamentos , Camundongos , Modelos Moleculares , Filogenia , Ratos
4.
Yao Xue Xue Bao ; 45(11): 1333-8, 2010 Nov.
Artigo em Chinês | MEDLINE | ID: mdl-21361031

RESUMO

Many major neurodegenerative diseases are associated with proteins misfolding and aggregation, which are also called "neurodegenerative conformational disease". The interaction of gene mutation and environmental factors are probably primary events resulting in oligomer and aggregate formations of proteins. Moreover, the dysfunctions of protein control systems, i.e. the ubiquitin-proteasome system and autophagy-lysosomal system, also contribute to the neurodegenerative process. The present review mainly summarizes protein misfolding and aggregation in the development of neurodegenerative conformational disease and the underling mechanisms, as well as upregulation of heatshock proteins as a promising treatment method for this kind of disease.


Assuntos
Proteínas de Choque Térmico/metabolismo , Doenças Neurodegenerativas/metabolismo , Dobramento de Proteína , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/genética , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Animais , Annona/química , Autofagia , Benzenoacetamidas/isolamento & purificação , Benzenoacetamidas/uso terapêutico , Proteínas de Choque Térmico/fisiologia , Humanos , Mutação , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/genética , Doenças Neurodegenerativas/patologia , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/genética , Doença de Parkinson/metabolismo , Doença de Parkinson/patologia , Fenóis/isolamento & purificação , Fenóis/uso terapêutico , Plantas Medicinais/química , Complexo de Endopeptidases do Proteassoma/metabolismo , Ubiquitina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...